samahealth.in

What It Is

SamaHealth is an AI-powered cardiac screening solution for India’s primary healthcare system, positioned as a front-line heart screening tool for “every primary clinic and every ASHA home visit.” Using SamaBeat, it captures roughly 20-second segments from four positions on a patient’s chest. The article reports a median screening time of 3.4 minutes, with high-risk signals escalated to a cardiologist within 90 seconds.

Core Capabilities

Its core value is not a single ECG strip, but multimodal acquisition that combines phonocardiography, single-lead ECG, and accelerometer data. On the AI side, it uses on-device TFLite models to perform low-latency triage for rhythm and abnormality risk; the article states inference takes under 800ms. The system also includes voice guidance, signal-quality gating, ambient-noise control, contact-pressure feedback, position-drift detection, and automatic retake prompts, making it suitable for use by primary-care workers.

Use Cases and Outputs

Typical use cases include rural household screening, screening camps with 200+ participants, rapid risk assessment at primary health centers, and follow-up rescreening for patients with hypertension or diabetes. It can track heart rate, HRV, sinus rhythm, atrial fibrillation, atrial flutter, ventricular tachycardia, S1/S2 splitting, murmurs, pulse pressure, waveforms, PWV proxy indicators, and more. Pilot data shows a 92% signal yield, but the article does not disclose key clinical performance metrics such as sensitivity, specificity, or AUC.

Pricing and Commercialization

The website does not publish pricing, hardware costs, subscription models, or usage-based fees. It only offers pilot scheduling and targets partnerships with state programs, district hospitals, and rural health NGOs. Because cost information is unavailable, its value for money can only be assessed conservatively.

Pros, Cons, and Who It’s For

Its advantages include an offline-first design, 14-day caching, on-device inference, and suitability for areas with weak connectivity. It also states asia-south1 data residency, on-device encryption, and append-only audit trails. Limitations include the fact that it is still in pilots in Bihar and Karnataka, with the article mentioning only a sample size of n=412; external validation and long-term real-world performance remain to be seen. It is suitable for public-health screening, primary-care programs, and organizations with supervised physician networks, but not for direct purchase by individual consumers.

Access from China and Alternatives

Information on access from China, payment, and local deployment is not disclosed, so these remain unknown. The product is tightly tied to India’s ABDM, ASHA, and local medical workflows. Deployment in China would require a fresh assessment of medical-device compliance, cross-border data transfer, Chinese voice support, and integration with local hospital systems. Alternative references include AliveCor, Eko Health, or domestic Chinese providers of AI ECG and primary public-health screening solutions.